Introduction Automated medication systems have been found to reduce errors in the medication process, but little is known about the cost-effectiveness of such systems. The objective of this study was to perform a model-based indirect cost-effectiveness comparison of three different, real-world automated medication systems compared with current standard practice. Methods The considered automated medication systems were a patient-specific automated medication system (psAMS), a non-patient-specific automated medication system (npsAMS), and a complex automated medication system (cAMS). The economic evaluation used original effect and cost data from prospective, controlled, beforeand-after studies of medication systems implemented at a Danish hematological ward and an acute medical unit. Effectiveness was described as the proportion of clinical and procedural error opportunities that were associated with one or more errors. An error was defined as a deviation from the electronic prescription, from standard hospital policy, or from written procedures. The cost assessment was based on 6-month standardization of observed cost data. The modelbased comparative cost-effectiveness analyses were conducted with system-specific assumptions of the effect size and costs in scenarios with consumptions of 15,000, 30,000, and 45,000 doses per 6-month period. Results With 30,000 doses the cost-effectiveness model showed that the cost-effectiveness ratio expressed as the cost per avoided clinical error was €24 for the psAMS, €26 for the npsAMS, and €386 for the cAMS. Comparison of the cost-effectiveness of the three systems in relation to different valuations of an avoided error showed that the psAMS was the most cost-effective system regardless of error type or valuation. Conclusion The model-based indirect comparison against the conventional practice showed that psAMS and npsAMS were more cost-effective than the cAMS alternative, and that psAMS was more cost-effective than npsAMS.
Introduction
Health authorities are concerned with improving patient safety and reducing the risk of preventable patient harm, including adverse drug events (ADEs) [1, 2] . Medication errors occur frequently during the medication administration process. They are not always harmful but may be associated with adverse events, which potentially lead to inconvenience, disability, or death of the patients [3] [4] [5] [6] [7] . ADEs associated with medication are one of the largest causes of harm to hospitalized patients, and studies have suggested that up to 40% of the ADEs in the medication process may be preventable [8] [9] [10] . Bates et al. specifically studied the relationship between medication errors and ADEs, and they found that 1 in every 100 medication errors resulted in an ADE [3] .
Adverse events might result in additional and prolonged treatment, longer hospitalization, re-admission, and increase in costs for both the patient and the health service. The costs of ADEs have been investigated by several studies and range from €970-3084 per event with €2092 as the mean cost of different studies [11] [12] [13] [14] [15] [16] [17] . Therefore, the medication administration process is an important area for safety improvements and for containing healthcare costs [9, 10, [18] [19] [20] [21] .
A variety of health technologies have been found to reduce medication error rates and have become important tools to improve medication safety in recent years [22] . Several studies have concluded that the implementation of an electronic medication administration record (eMAR) reduced medication error rate in lieu of paper-based prescriptions [23] [24] [25] [26] [27] [28] . Patient identification and alignment with administration records using barcode medication administration (BCMA) in combination with eMAR has also been shown to enhance the accuracy of medication administration [29] [30] [31] . A study by Poon et al. supported these results as they found that BCMA and eMAR combined reduced the occurrence of preventable ADEs by 50.8% [32] . Bonkowski et al. found a reduction of 80.7% of medication administration errors [33] , and Truitt et al. found a reduction in ADEs of 22% when BCMA and eMAR were implemented together [34] .
Automated dispensing is another previously tested technology, but studies have so far shown inconsistent results [35, 36] . Fanning et al. investigated implementation of automated dispensing cabinets (ADCs) in an emergency department and found a 64.7% reduction in medication selection and preparation errors [37] . In 2014 Cousein et al. compared a combination of automated dispensing and ADCs in a short-stay geriatric unit with a conventional ward stock system and found a 53% reduction in medication administration errors with the new system [38] . In contrast to these findings, Cochran et al. investigated the role of ADCs and BCMA in reducing medication error rates, but could not identify significant improvement in dispensing errors [39] .
Franklin et al. assessed the impact of a closed-loop system in combination with eMAR, automated dispensing, and BCMA in a surgical ward and found it reduced the proportion of errors in the medication administration process [40] . These results were supported by a recent study of Hwang et al. who found that a closed loop system implemented in a teaching hospital effectively could prevent potential ADEs [41] .
The effectiveness of medication systems has been evaluated extensively in different settings, in terms of patient safety, but the cost-effectiveness of technologies that reduce medication errors is also relevant for decisions about implementation of such systems.
Only a small number of studies have evaluated the costeffectiveness of different systems. Wu et al. evaluated the cost-effectiveness of an electronic medication ordering and administration system in relation to avoided ADEs, using effect data from previous studies. They concluded that further research was required to determine the potential of the systems to reduce ADEs, and thus to assess the value of these technologies [42] . Forrester et al. found a computerized provider order entry to be less costly and associated with fewer medication errors compared to paper-based prescribing in an ambulatory setting, and concluded that the technology represents good value for money [43] , and Westbrook et al. determined that a hospital electronic medication management system was cost-effective because it reduced the risk of potential ADEs at a lower cost [44] . A study by Vermeulen et al. investigated the cost-effectiveness of an electronic medication order entry system and found an incremental cost-effectiveness ratio (ICER) of €3.54 for medication errors, and €322.70 for preventable adverse drug events [45] . In a previous study we found ICERs of €2.91 per avoided procedural error, and €19.38 per avoided clinical error from a closed-loop automated medication system [46] .
However, it is difficult to compare the results of individual studies that evaluate the cost-effectiveness of AMSs in different clinical settings and use different methods for measurements of effectiveness and costs. This implies the need for a standardized framework to enable realistic comparisons. To our knowledge, a comparative analysis of the cost-effectiveness of different medication systems has not yet been performed. The objective of this study was to perform a model-based indirect comparison of the costeffectiveness of different medication systems each compared against conventional practice by comparing the costeffectiveness of different combinations of four functional elements; eMAR, automated unit dose dispensing (patient or non-patient specific), ADC, and BCMA.
Methods

Design, Recruitment, and Setting
The economic evaluation was conducted using data from two prospective, controlled, before-and-after studies of the costs and effects of three different medication administration systems. The three medication systems were implemented in hospital wards identified based on an assessment of clinical ward medical tasks, medication profile, and patient flow (duration of stay). Dialogues were held with potential intervention wards and those with an obvious interest were recruited. Control wards were recruited to match the intervention wards focusing on similar procedures in the medication handling process and comparable medication profile. All participating wards were identified within the Central Denmark Region and all received medical supplies from the Hospital Pharmacy. The hospital pharmacy service at all wards was based on ward stock supply, where standard medications were stored in the ward's medicine storage room.
The first AMS effectiveness study is described in Risør et al. [47] . It was performed from May 2013 to February 2014 in two hematological wards (a control and an intervention unit) and estimated difference-in-difference effects from the two wards at baseline and 4-month post-implementation effects of the patient-specific AMS.
The second unpublished study compared two different AMS approaches and was conducted in two acute medical units (control and intervention) during December 2013 to August 2015. This study included three observation periods with collection of effect data during a 3-week period as initial baseline and two subsequent follow-up periods at 10 and 20 months. The complex automated medication system (cAMS), which combines the electronic medication administration records (eMAR), automated drug dispensing, an automated dispensing cabinet (ADC), and barcodeassisted medication administration (BCMA) was implemented immediately after the baseline data collection and was in use until the end of the first follow-up data collection. The ADC was subsequently removed from the intervention unit and a non-patient-specific automated medication system (npsAMS) was implemented. The effect-data for this system were collected in the second follow-up data collection.
Further information describing the participating wards and their number of patients, doses of medication, number of staff, etc. is provided in Supplementary File 1.
The Medication Systems
All participating hospital wards relied initially (at baseline) on manual processes for medication handling. The hospital pharmacy and pharmaceutical staff controlled the delivery and storage of drugs from wholesalers and ward stock supplies. Physicians prescribed medications and entered prescription data and changes directly into the ward-based eMAR after their ward rounds. Nursing staff managed the dispensing of individual patients' medication. The nurses dispensed the medication in the ward's medicine room and the eMAR was used to identify each individual process of medicine administration. Medication was dispensed in medicine boxes labeled with the patient's name and social security number. Medication from the medicine boxes was administered to the patient at each administration time.
The first study implemented an AMS with patientspecific unit dose dispensing (psAMS). The psAMS implementation comprised three core elements: (1) a pharmacist-performed technical control of prescriptions in the eMAR before forwarding orders to an automated dispensing machine. This ensured that most prescribed medication was within the assortment of the automated dispensing machine; (2) automated unit dose dispensing (one dose of medication per dose bag) of medication packed for individual patients and delivered for each 24 h; and (3) BCMA with bedside barcode scanning using a personal digital assistant (PDA) of the packed dosage and patient wristband before administration [47] .
The second study implemented a complex automated medication system (cAMS) and a non-patient-specific automated medication system (npsAMS).
In the cAMS the ADC was connected to the eMAR and was accessed through eMAR ordinations. Only the dispensing nurse could withdraw medication prescribed to a specific patient. Technical control of the prescriptions in the eMAR was performed by a pharmacist and ensured that the medications prescribed were actually available in the ADC. Tablets and suppositories in the ADC were primarily stored as unit-dose packages prepared by the automated dispensing machine. Other medications were used in their original packaging. BCMA was performed when the medicine was administered to the patient.
The npsAMS consisted of the same core elements as the psAMS; however, there was no pharmacist-performed technical control of prescriptions. The dispensed medication was delivered as unit dose bags and stored in the medication room at the ward instead of being packaged for individual patients. Documentation of the medication administration was performed with BCMA in line with the psAMS.
The studies of the three medication systems are shown schematically in Fig. 1 , and complete details for each system are provided in Supplementary File 2.
Data Collection
Measurement of Effects
The primary outcome measure was errors in the medication administration process. The proportion of errors was determined by dividing the number of doses associated with one or more errors by the number of opportunities for error. The ''number of opportunities for error'' was defined as the sum of doses given plus doses prescribed but omitted, and the number of opportunities for error corresponded to the total number of doses. This method has been advocated by Allan and Barker [48] .
An error in the medication administration process was defined as ''the administration of a dose of medication that deviated from the eMAR prescription, from standard hospital policy, or from written procedures'' [46, 47] . The medication administration errors were further divided into clinical and procedural errors as previously done by Westbrook et al. [49] . The error types observed in this study are defined in Table 1 .
The power calculation estimated the required number of observations needed to ensure sufficient statistical power by assuming an error rate of 0.22, corresponding to the average error rate in the dispensing/administration stage found in an earlier Danish study [6] , the power of 80, and an expected relative reduction in errors of 30%, which was considered to be clinically relevant by the hospital ward managers and staff. This indicated a required sample size of 511 observed doses at each participating ward in all data collection periods (baseline and follow-up).
Each observation period was conducted over a 3-week period prior to implementing the AMS and again afterwards. The measurement of clinical and procedural errors was done by six dedicated clinical pharmaconomists who overtly and directly observed nurses administer medication. The observers followed a protocol to ensure reliable and valid observations and intervened in the medication administration process only to prevent severe errors and prevent harm to patients. An initial one-day pilot data collection was conducted to train observers, test the observation protocol, and reduce interobserver variability by aligning observed errors with defined error types.
All observations were recorded on paper-based forms and entered into a digital spreadsheet (Microsoft Office Excel ver. 2003). The observations were then compared with the medications prescribed in the eMAR and the written procedures. Any discrepancies were considered as errors and categorized according to Table 1 . Fig. 1 Flowchart of the included studies of the three automated medication systems. psAMS patient specific automated medication system, cAMS complex automated medication system, npsAMS non-patient specific automated medication system All registered medication administrations performed by nurses in the participating wards were observed during the data collection. Because of technical limitations of the AMSs, injectable medicine and liquid formulations were excluded from the study.
Economic Evaluation
The economic evaluation compared the AMSs with the conventional medicine delivery system in which medicines were delivered in original packaging and dispensed by nurses in the medication room at the ward. The cost analysis and a cost-effectiveness analysis were conducted within a 6-month time frame. The cost of errors from potential adverse drug events, patients needing additional treatment, increased length of stay, etc. was beyond the scope and feasibility of this study and was thus not included in the cost measurement.
The cost analysis used a hospital perspective and a short-term incremental costing approach based on the assumption that only the costs related to medicine delivery and handling would change as a consequence of the implemented medication systems. Costs common to the AMS and the conventional system, such as the costs of medicines unavailable within the system, were not recorded. The medicine delivery procedures were assumed to have no influence on overhead costs including hospital administration, cleaning, and rent. The costs of medicines were not expected to change as a result of the intervention and were recorded but not included in this analysis.
We used micro-level costing to maximize the accuracy of estimated resource use for individual items and services. We conducted field studies to identify items related to cost activities as well as costs that varied with changes in AMS. This information was used to design a method to collect on-site data pertaining to resource use and unit costs.
Costs of the automated dispensing machine, the ADC, and the development of eMAR-PDA and PDA interfaces were calculated by standard annuitization methods to annual equivalent costs by using an interest rate of 5% and the expected annuity of the investments [50] . Assumptions about the lifetime of each device and equipment were obtained from the manufacturers and verified by local users and managers.
It is current costing practice within the hospital pharmacy to inflate all pharmacy services by 30% (information obtained from the economic office in the hospital pharmacy). To account for systematic differences between the Table 1 Definition of identified error types in the medication administration process adapted from Risør et al. [46, 47] Error type Definition
Clinical errors
The patient did not receive the medication as prescribed in the eMAR [51] ).
Discounting was not necessary as the time frame was less than a year.
The included cost-elements are described in the following formulae:
The total costs of current practice (alternative 1) (TC 1 ) is the sum of the handling costs (C H ), waste costs (C W ), and the costs of pharmaceutical services (C ps ). The handling cost is the number of administered doses multiplied by the labor costs and added to the packaging costs.
Total costs of the medicine administrative systems (alternative 2 (TC 2 )) is the sum of handling costs (C H ), waste costs (C W ), costs of pharmaceutical services (C ps ), costs of the PDA (C PDA ), and the costs of dose bags (C db ). The C db equals the number of administered dose bags multiplied by the unit cost per dose bag. When calculating the costs of the cAMS the cost of the ADC was added (C ADC ).
Resource Quantities and Unit Costs
Recourse use and unit costs are described in Table 2 .
Handling time was estimated based on time-motion studies of the medication handling processes at the participating wards. The observation of tablet dispensing and administration followed a pre-specified protocol and one observer performed all time-motion studies. The observation time included only tablet handling activities and did not include injectable medicine activities. The time-motion observation protocol was designed to detect a wide variety of factors expected to affect time usage such as gender, age, and working experience. Supplementary File 3 presents the raw data in terms of number of observations and means and range of values.
Un-packaging time was a cost introduced by the psAMS only, where service staff managed the unpacking of medicine deliveries.
Waste costs (C W ) were estimated based on the cost of surplus medication collected over a period of 14 days. The wasted tablets were identified and counted, and pharmaceutical staff identified the unit cost of tablets. Data on the number of wasted dose bags were obtained from the administrative systems at the hospital pharmacy.
The costs of pharmaceutical service (C ps ) included the costs associated with expiry control, consumption surveillance, and medicine ordering at the wards. The time used at the wards was recorded for 2 weeks at both baseline and follow-up.
The unit cost per dose bag was calculated as the total costs of the automated dispensing machine distributed per produced dose bag in full-scale implementation (2,045,000 unit dose bags per year). The unit cost per dose bag was derived from the purchase costs of the dispensing machine, facilities, and the estimated annual operating cost of the dispensing machine. The specific assumptions used and the calculation of unit cost per dose bag are presented in Supplementary File 4.
Data Analysis
Logistic regression with the presence of error as the dependent variable was used to determine the change in errors after the three medication systems were implemented. Time (baseline/follow-up), group (intervention ward/control ward), and interaction between time and group were the independent variables. For every opportunity for error, the dependent variable was coded as zero in the case of no error, and coded as 1 when one or more errors occurred. Estimates for the odds-ratio (OR) and 95% confidence intervals (CIs) for the interaction variable (the ''difference-in-difference'' estimate) were considered the primary results for the reduction in errors for the intervention ward at follow-up. In addition, analyses of the sub-types clinical and procedural errors were performed separately to assess the importance of ''potential clinical errors'' in relation to actual clinical errors.
The Analytic Model
The number of medication doses administered over a 6-month period in each of the hospital wards differed by more than 20,000 doses, which prevented a direct costeffectiveness comparison. In order to conduct an indirect comparative analysis, we standardized the observed effect size and costs to 15,000, 30,000, and 45,000 doses in a 6-month period.
The effectiveness assumptions were derived based on an estimated summed baseline proportion of administration (procedural and clinical) errors, which were calculated adding actual baseline observations from the intervention ward, and all observations from the control wards. The estimated follow-up proportion of errors was calculated by multiplying the summed baseline proportion by the actual obtained odds ratios from each of the AMSs studies.
The estimated number of medication errors in a 6-month period was calculated by multiplying the specific proportion of errors by the number of administered doses in each consumption scenario. The number of avoided medication errors was calculated by subtracting the estimated number of errors at follow-up from the number of errors at baseline.
The use of ward-based pharmacy service, number of PDAs, number of wasted tablets, and number of wasted dose bags from the different study settings were normalized into an estimated resource use based on original data in each consumption scenario, which was used in the model ( Table 2 ). The observed medication handling time per administered dose was standardized into a mean baseline handling time preserving the handling time difference from baseline to follow-up for each of the AMSs ( Table 2) .
The proportion of errors, handling time, and waste cost were all observed parameters, thus possibly introducing uncertainties. We conducted non-parametric simulations based on the mean/OR and standard error of the mean on the observed parameters [52] to mitigate the uncertainty associated with the incremental cost-effectiveness ratio Source: This investment was calculated as the annual equivalent cost by using an interest rate of 5% and an annuity of 5 years Cost per dose bag 0.58
Source: The unit cost per dose bag was the total costs of the automated dispensing machine distributed per produced dose bag in full-scale estimation (2,045,000 unit dose bags per year). The unit cost per dose bag was derived from the purchase costs of the dispensing machine, facilities, and the estimated annual operating cost of the dispensing machine
The purchase costs of the automated dispensing machine, eMAR integration, and development of the PDA application were calculated to an annual equivalent cost using an interest rate of 5% and an annuity of 17 years (calculations are presented in Supplementary file 4) Cost per 6 months of the ADC 67,571
Source: the purchase cost of the ADC and its integration with the eMAR was calculated as an annual equivalent cost using an interest rate of 5% and an annuity of 10 years. Service agreements, licensing, and the operation of the helpdesk were included in the cost of the ADC PDA personal digital assistant, psAMS patient-specific automated medication system, npsAMS non-patient-specific automated medication system, cAMS complex automated medication system, ADC automated dispensing cabinet n errors number of observed doses with one or more errors, p errors proportion of errors *Same baseline (only counted once in the summed baseline presented in Table 4 ) Summed baseline: calculation of the proportion of errors using raw data from the control group (baseline and follow-up) and intervention group (baseline) from both studied settings Estimated proportion of errors at follow-up: calculated as the summed baseline multiplied by the specific OR n errors number of observed doses with one or more errors, p errors proportion of errors, OR odds ratio from analysis of the raw data of each study of the three AMSs, 95% CI confidence interval around the OR (ICER). The simulation produced 1,000 random samples of cost-effectiveness pairs for each medication system and consumption scenario. Incremental cost-effectiveness ratios for each iteration of the simulation were plotted in a scatterplot (Supplementary File 5) . The probability of costeffectiveness related to different assumed values per avoided error was interpreted as cost-effectiveness acceptability curves. To test the impact on results of the additional investment in an ADC, which might be gifted or funded by external finances and thus not a burden on the hospital budget, a sensitivity analysis was performed excluding the costs of ADC.
Results
Effectiveness
The effectiveness of the technologies in reducing the proportion of medication administration errors is shown in Table 3 . The psAMS showed a statistically significantly reduced proportion of both administration errors and subtypes procedural and clinical errors [47] . The npsAMS showed a statistically significant reduction in clinical errors and a non-significant reduction in both administration errors and procedural errors. The cAMS showed a statistically significant lower proportion of administration errors and of procedural errors. The proportion of clinical errors reduced as well, but was non-significant.
The standardized baseline proportions and the odds ratio from the different medication systems used to calculate the estimated follow-up proportion and number of avoided errors applied in the cost-effectiveness analysis ares presented in Table 4 .
Costs
Total and incremental costs for each technology and each consumption scenario are shown in Table 5 . For clarity, only results from the 30,000 doses scenario are described, although results of the two other scenarios appear in the table. For the psAMS the total incremental cost was €19,477, corresponding to an incremental cost per administered dose of €0.65. For the npsAMS, the total incremental cost was €17,132, corresponding to an incremental cost per administered dose of €0.57. For the cAMS the total incremental cost was €102,653, corresponding to an incremental cost per administered dose of €3. 42 .
These results show only a small cost difference between the psAMS and npsAMS. The cAMS was associated with a larger cost caused by the additional investments and operation of the ADC. The incremental cost per dose decreased with higher number of administered doses for all technologies, however, primarily so for the cAMS. This relates to a higher fixed cost of the cAMS technology compared to the psAMS and npsAMS.
Incremental Cost-Effectiveness
Comparison of the incremental costs and effects of the three technologies is shown in Table 6 .
The psAMS could avoid 812 clinical errors during a 6-month period and the cost per avoided clinical error was €24. The npsAMS resulted in 671 avoided clinical errors at a cost of €26 per avoided clinical error. The cAMS could avoid 266 clinical errors and the cost was €386 per avoided clinical error.
The cost-effectiveness acceptability curves (CEACs) for each AMS at the 30,000-doses scenario are shown in Fig. 2 psAMS patient-specific automated medication system, npsAMS non-patient-specific automated medication system, cAMS complex automated medication system Table 6 Incremental costs (C), number of avoided errors (E) and C/E may be expected to be cost-effective at a given value per avoided clinical error. Comparison of the curves shows that the psAMS is the most cost-effective of the three systems, being 100% cost-effective with an assumed value over €24 for both administration errors and subtypes. For administration and the subtype procedural errors, npsAMS is more cost-effective than cAMS at a value of €50; however, if the value were increased to 100 € per avoided administration or procedural error the cAMS would reach 100% cost-effectiveness, whereas the npsAMS only reaches 65% for procedural and 90% for administration errors. This implies a trade-off between chance of cost-effectiveness and value assumption. If the decision makers value an avoided error more than 100 € then the cAMS is more cost-effective than the npsAMS.
. The CEACs illustrate to what degree the technology
For clinical errors both psAMS and npsAMS reaches 100% cost-effectiveness probability at a valuation over €24 and €26, respectively, whereas cAMS only reaches a 25% chance of being cost-effective at a value over €150 per avoided clinical error.
The incremental costs of cAMS were higher than for the other two systems because of the additional investment in an ADC. To test the impact of this specific investment, we performed a sensitivity analysis where this cost was excluded. The sensitivity analysis showed the same overall picture, but at a lower valuation. The CEAC from the sensitivity analysis is shown in Fig. 3 . The psAMS was still the most cost-effective alternative. The cAMS seemed to be a better alternative than npsAMS when emphasizing a reduction in administration or procedural errors at a threshold value of €25. The npsAMS was more cost-effective than cAMS when emphasizing a reduction in clinical errors, because the cAMS only reaches a 60% chance of being cost-effective in relation to this subtype no matter the assumed value.
Discussion
In this study we developed and applied a comparative model to evaluate the cost-effectiveness of three different automated medication systems. The evaluation showed that the psAMS was the most cost-effective system for avoiding administration errors in general as well as procedural and clinical errors.
Strengths and Weaknesses
The model-based economic evaluation was based on empirical data obtained from real-world implementation of different technologies in different hospital settings and illustrates how indirect comparisons can be made between hospital units with different specialties and error pattern. Real-world data were collected prospectively for costs and effects for each system. Methods applied for data collection were observations, registrations, and extractions from pharmacy and hospital databases to obtain real-life unit costs. Data collections were carefully organized to minimize the risk of bias, and the measurement methods applied were similar in all studies.
In the studies of effectiveness, the control wards had a lower proportion of errors at baseline than the intervention ward. This is, of course, a limitation of the study since this variation was unexpected. It is unclear what caused the lower proportion of errors in the control ward at baseline, but one reason could be the slightly lower occupancy percentage, more employees, and fewer patients at the control wards (Supplementary File 1) ; these factors could indicate that the intervention wards experienced a higher workload, which has been found to be an error-provoking condition [53] . What might have caused the variation in the administration error rate over time in the control ward remains unclear. However, this could also have been caused by organizational changes, parallel projects at the control wards focusing on medication safety, or perhaps by changes in the nursing staff. The difference-in-difference analyses, which focused on the change over time (baseline to follow-up) between the two groups, accounted for the baseline differences between groups as well as the change in the control ward over time, and in this study, might lead to an underestimation of the results.
In the estimated baseline proportion of errors for the model-based analysis, we standardized the baseline proportion from all control observations and the intervention baseline, thus equalizing the baseline differences in the model-based analysis. We then used the OR from each study to estimate the follow-up proportion of errors. In this way the estimated number of errors and avoided errors were adjusted by the ''control level,'' which lowered the risk of overestimating the effect and cost-effectiveness of the technologies.
To account for the inherent differences in productivity among the studied settings we standardized the evaluation model. The model included testing of the uncertainties around effect and cost estimates by simulations, and these Fig. 2 Cost-effectiveness acceptability curves for scenarios with 30,000 6-monthly administered doses. psAMS patient specific automated medication system, npsAMS non-patient specific automated medication system, cAMS complex automated medication system uncertainties were represented in the cost-effectiveness acceptability curves. Observed data from the different wards were standardized into three generic consumption scenarios for comparative purposes. Such standardization of costs and effects generated a hybrid ward to simply allow the comparison of effectiveness across different clinical settings.
The applied model compared each of the automated technologies with standard practice of medicine administration. Thus, the comparison between the different alternatives was indirect and limited by the methodology employed. Original data were extrapolated in the model, which might introduce systematic bias if any of the assumptions made were incorrect. However, the model was carefully developed with full transparency of the original data and assumptions made in the analysis. We initially developed the cost-effectiveness analysis as a deterministic model in an Excel spread sheet, where the data and model structure were easy to communicate and modify. Subsequently, we developed the model using Stata scripts, where the inherit uncertainty in the observed parameters was directly applied to model the stochastic uncertainty. The full data process was documented in a Stata do-file to ensure transparency and reduce errors. The final results and sensitivity analyses were produced using the Stata model.
Results from Other Studies
To our knowledge, a comparative cost-effectiveness analysis of different automated medication systems has not been performed previously. A few studies have evaluated the costs, cost-benefit, or cost-effectiveness of medication administration technologies in isolation. Kheniene et al. performed a cost-benefit analysis of an ADS implemented in an intensive-care setting and concluded that the ADS is expected to generate cost-savings [54] . However, they measured nurse and pharmacy technician working time, the cost of drug storage, and the cost of expired drugs, but did not include investment costs, and therefore potentially underestimated the overall costs. Chapuis et al. performed a financial analysis of ADSs implemented in three surgical intensive care units, arrived at similar results, and Fig. 3 Cost-effectiveness acceptability curves-sensitivity analysis excluding the cost of the automated dispensing cabinet. psAMS patient specific automated medication system, npsAMS non-patient specific automated medication system, cAMS complex automated medication system concluded that the system showed a high return on investment for the hospital [55] . Westbrook et al. combined effectiveness data from a hospital electronic medication management system with observed ADEs or potential ADEs from medical records, and assigned published costs of ADEs estimating the potential cost savings of the new technology compared to a paper-based approach. They concluded that the electronic system was more effective and less expensive [56] . These results are supported by the findings of Forrester et al., who concluded that a computerized provider order entry was cost-effective and represented good value for the investment [43] . Vermeulen et al. investigated the cost-effectiveness of an electronic order entry system and derived cost-effectiveness ratios expressed by cost per avoided medication error and found that the additional costs were within an acceptable range [45] .
Most automated medication systems are complex interventions implemented over a longer period of time in different settings, which means that cost assessments are challenging to conduct [22] . From a decision-maker's perspective prioritizing between different systems seems impossible without a feasible way to compare the costeffectiveness between studies. The model-based analysis performed in this study used original data and provides a framework to investigate and compare the costs and effects of different automated medication systems implemented in different settings.
The results still need some translation into a decisionmaking context. Previous studies have investigated the saved costs of avoided ADE, which are relevant for costbenefit assessments. In this study we investigated the proportion of administration, procedural, and clinical errors, and expressed the cost-effectiveness as cost per avoided error without assigning a monetary value to these errors. Errors happen frequently; however, only a minority of these may be considered as serious errors with potential risk of harming the patient. Only errors that affect the outcome for patients or costs associated with these errors are relevant for the economic evaluation. Assuming an average cost of errors in order to estimate the benefit of the intervention would introduce a new set of assumptions and uncertainties that may bias and limit the validity of the result. In this report the cost-effectiveness analysis enables decision makers to form an opinion of the value of an avoided clinical error and to determine whether the intervention should be considered ''good value for money.' ' 
Conclusion
This model-based indirect comparison against the conventional alternative showed that psAMS was the most cost-effective alternative in all scenarios with all realistic values of avoided errors. The psAMS showed a 100% probability of being cost-effective at a valuation of €25 per avoided error regardless of error type.
